PT1532141E - Derivados de 2-pirrolidin-2-il-[1,3,4]-oxadiazole e sua utilização como antidepressivos - Google Patents

Derivados de 2-pirrolidin-2-il-[1,3,4]-oxadiazole e sua utilização como antidepressivos

Info

Publication number
PT1532141E
PT1532141E PT03794933T PT03794933T PT1532141E PT 1532141 E PT1532141 E PT 1532141E PT 03794933 T PT03794933 T PT 03794933T PT 03794933 T PT03794933 T PT 03794933T PT 1532141 E PT1532141 E PT 1532141E
Authority
PT
Portugal
Prior art keywords
antidepressants
pyrrolidin
same
oxadiazole derivatives
oxadiazole
Prior art date
Application number
PT03794933T
Other languages
English (en)
Portuguese (pt)
Inventor
Hagen-Heinrich Hennies
Helmut Buschmann
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of PT1532141E publication Critical patent/PT1532141E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT03794933T 2002-08-30 2003-08-25 Derivados de 2-pirrolidin-2-il-[1,3,4]-oxadiazole e sua utilização como antidepressivos PT1532141E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10240818A DE10240818A1 (de) 2002-08-30 2002-08-30 Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate

Publications (1)

Publication Number Publication Date
PT1532141E true PT1532141E (pt) 2010-11-02

Family

ID=31983895

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03794933T PT1532141E (pt) 2002-08-30 2003-08-25 Derivados de 2-pirrolidin-2-il-[1,3,4]-oxadiazole e sua utilização como antidepressivos

Country Status (18)

Country Link
US (1) US7105538B2 (enExample)
EP (1) EP1532141B1 (enExample)
JP (1) JP2006506348A (enExample)
CN (1) CN100390168C (enExample)
AR (1) AR041093A1 (enExample)
AT (1) ATE484503T1 (enExample)
CA (1) CA2497078A1 (enExample)
CY (1) CY1110913T1 (enExample)
DE (2) DE10240818A1 (enExample)
DK (1) DK1532141T3 (enExample)
ES (1) ES2351119T3 (enExample)
MX (1) MXPA05002298A (enExample)
PE (1) PE20040983A1 (enExample)
PL (1) PL375627A1 (enExample)
PT (1) PT1532141E (enExample)
RU (1) RU2324694C2 (enExample)
SI (1) SI1532141T1 (enExample)
WO (1) WO2004024725A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2291080E (pt) 2008-05-14 2015-10-30 Scripps Research Inst Novos modelamodeladores dos recetores da esfingosina fosfato
RU2417995C1 (ru) * 2009-09-21 2011-05-10 Государственное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ГОУ ВПО "КубГТУ") Способ получения 3-(2-замещенных-1,3-оксазол-4-ил)пиридин-2(1н)-онов
CN103420998A (zh) * 2012-05-16 2013-12-04 苏州爱斯鹏药物研发有限责任公司 一种新型噁二唑衍生物的合成方法
DK2855453T3 (en) 2012-06-04 2017-02-06 Actelion Pharmaceuticals Ltd Benzimidazol-proline derivatives
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
BR112015007516A2 (pt) * 2012-10-10 2017-07-04 Actelion Pharmaceuticals Ltd antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona
CN105051040A (zh) * 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
CN103333165B (zh) * 2013-07-01 2016-02-24 河南理工大学 2-苯基-5-(3,4-二甲基)吡咯基-1,3,4-噁二唑及制备方法
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
CN111978311B (zh) * 2019-05-21 2024-05-31 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2215949B1 (enExample) * 1973-02-01 1976-07-02 Delalande Sa
US4784998A (en) * 1987-04-06 1988-11-15 Bristol-Myers Company 1,3,4-oxadiazole pyschotropic compounds
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
CN1382140A (zh) * 1999-07-09 2002-11-27 奥索-麦克尼尔药品公司 具有神经营养活性的吡咯烷和哌啶、以及含有它们的相关组合物
JP2001247569A (ja) * 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives

Also Published As

Publication number Publication date
MXPA05002298A (es) 2005-06-08
JP2006506348A (ja) 2006-02-23
EP1532141B1 (de) 2010-10-13
SI1532141T1 (sl) 2010-12-31
DK1532141T3 (da) 2010-11-22
CN1678609A (zh) 2005-10-05
ES2351119T3 (es) 2011-01-31
US20050187260A1 (en) 2005-08-25
CA2497078A1 (en) 2004-03-25
US7105538B2 (en) 2006-09-12
PE20040983A1 (es) 2005-01-12
AR041093A1 (es) 2005-05-04
AU2003264097A1 (en) 2004-04-30
EP1532141A1 (de) 2005-05-25
PL375627A1 (en) 2005-12-12
RU2324694C2 (ru) 2008-05-20
RU2005109164A (ru) 2006-01-20
DE50313185D1 (de) 2010-11-25
DE10240818A1 (de) 2004-05-13
CY1110913T1 (el) 2015-06-10
CN100390168C (zh) 2008-05-28
ATE484503T1 (de) 2010-10-15
WO2004024725A1 (de) 2004-03-25

Similar Documents

Publication Publication Date Title
IL162266A (en) Substituted 2-thio-3,5-dicyano-4- phenyl-6-aminopyridines and the use of the same
IL159086A0 (en) 3-aryl-5-aryl- [1, 2, 4] -oxadiazole derivatives and pharmaceutical compositions containing the same
EG25011A (en) Amino-piperidin-1-yl-xanthines, the production thereof and the use of the same as medicaments.
IL176005A0 (en) 2,6-bisheteroaryl-4-aminopyrimidine derivatives and pharmaceutical compositions containing the same
ZA200407986B (en) Substituted phenylacetamides and their use as glucokinase activators.
AU2003233010A8 (en) Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
IL176283A0 (en) Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
AU2001256184A1 (en) 6-aminoalkyl-dihydropyrimidines and the use thereof as medicaments against viraldiseases
AU2002328343A1 (en) Wax-based compositions and the use thereof as body care agents
PT1757606E (pt) Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
HUP0401564A3 (en) Diaryl cycloalkyl derivatives, the use thereof as ppar activators and pharmaceutical compositions containing thereof
IL193234A0 (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
IL219671A0 (en) 1,2- benzoxazoles and use thereof in the preparation of a medicament
EP1577317A4 (en) NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, MEDICINAL COMPOSITIONS COMPRISING SAID DERIVATIVES AND MEDICAL USE OF SAID DERIVATIVES
HUP0402489A3 (en) 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
IL174479A (en) The derivatives of myastrin, pharmaceutical preparations containing them and their uses
IL166821A0 (en) Novel 1,4-diazabicycloalkane derivatives their preparation and use
EG23929A (en) Isoxazolines derivatives and their use as antidepressants
PL375627A1 (en) 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole derivatives and the use of the same as antidepressants
IL164887A0 (en) Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
TWI348382B (en) N-acetylglucosamine derivatives, and the use thereof
IL175303A0 (en) Oral formulations for 5-ht-receptor agonists, uses and methods of treatment employing the same
PL1786759T3 (pl) Nowe pochodne 3,5-seko-4-norcholestanowe i ich zastosowanie
HRP20040691A2 (en) 2'-halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine and the use thereof as a drug
AU2003264097B2 (en) 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole derivatives and the use of the same as antidepressants